This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Comment

. 2005;366(9496):1510-2.

doi: 10.1016/S0140-6736(05)67575-7.

The end of beta blockers for uncomplicated hypertension?

D Gareth Beevers¹

Affiliations

PMID: 16257329
DOI: 10.1016/S0140-6736(05)67575-7

Comment

The end of beta blockers for uncomplicated hypertension?

D Gareth Beevers. Lancet. 2005.

. 2005;366(9496):1510-2.

doi: 10.1016/S0140-6736(05)67575-7.

Author

D Gareth Beevers¹

Affiliation

¹ University Department of Medicine, City Hospital, Birmingham B18 7QH, UK. ruby.stone@swbh.nhs.uk

PMID: 16257329
DOI: 10.1016/S0140-6736(05)67575-7

No abstract available

PubMed Disclaimer

Comment in

Beta blockers for the treatment of primary hypertension.
Khan N, McAlister FA. Khan N, et al. Lancet. 2006 Jan 21;367(9506):208; author reply 210. doi: 10.1016/S0140-6736(06)68027-6. Lancet. 2006. PMID: 16427485 No abstract available.
Beta blockers for the treatment of primary hypertension.
Ball SG. Ball SG. Lancet. 2006 Jan 21;367(9506):209-10; author reply 210. doi: 10.1016/S0140-6736(06)68029-X. Lancet. 2006. PMID: 16427486 No abstract available.
Beta blockers for the treatment of primary hypertension.
Cruickshank JM. Cruickshank JM. Lancet. 2006 Jan 21;367(9506):209; author reply 210. doi: 10.1016/S0140-6736(06)68028-8. Lancet. 2006. PMID: 16427487 No abstract available.

Comment on

Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis.
Lindholm LH, Carlberg B, Samuelsson O. Lindholm LH, et al. Lancet. 2005 Oct 29-Nov 4;366(9496):1545-53. doi: 10.1016/S0140-6736(05)67573-3. Lancet. 2005. PMID: 16257341 Review.

Similar articles

Beta-blockers for hypertension.
Hoffmann F. Hoffmann F. CMAJ. 2007 Mar 27;176(7):971; author reply 971-2. doi: 10.1503/cmaj.1060198. CMAJ. 2007. PMID: 17389450 Free PMC article. No abstract available.
Beta-blockers for hypertension.
Siebenhofer A, Horvath K, Jeitler K, Gratzer T. Siebenhofer A, et al. CMAJ. 2007 Mar 27;176(7):971; author reply 971-2. doi: 10.1503/cmaj.1060199. CMAJ. 2007. PMID: 17389449 Free PMC article. No abstract available.
Beta-blockers for hypertension.
Carlberg BC. Carlberg BC. CMAJ. 2007 Mar 27;176(7):971; author reply 971-2. doi: 10.1503/cmaj.1060205. CMAJ. 2007. PMID: 17389448 Free PMC article. No abstract available.
The evolving role of β-adrenergic receptor blockers in managing hypertension.
Poirier L, Lacourcière Y. Poirier L, et al. Can J Cardiol. 2012 May;28(3):334-40. doi: 10.1016/j.cjca.2012.04.001. Can J Cardiol. 2012. PMID: 22595449 Review.
Why beta-blockers should not be used as first choice in uncomplicated hypertension.
De Caterina AR, Leone AM. De Caterina AR, et al. Am J Cardiol. 2010 May 15;105(10):1433-8. doi: 10.1016/j.amjcard.2009.12.068. Epub 2010 Mar 30. Am J Cardiol. 2010. PMID: 20451690 Review.

See all similar articles

Cited by

For Debate: The 2023 European Society of Hypertension guidelines - cause for concern.
Shantsila E, Beevers DG, Lip GYH. Shantsila E, et al. J Hypertens. 2024 Jun 1;42(6):948-950. doi: 10.1097/HJH.0000000000003733. Epub 2024 Apr 12. J Hypertens. 2024. PMID: 38634468 Free PMC article.
Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.
Koracevic G, Micic S, Stojanovic M, Tomasevic M, Kostic T, Velickovic Radovanovic R, Lovic D, Djordjevic D, Randjelovic M, Koracevic M, Ristic Z. Koracevic G, et al. Hypertens Res. 2020 Jul;43(7):591-596. doi: 10.1038/s41440-020-0449-6. Epub 2020 May 7. Hypertens Res. 2020. PMID: 32382156 Review.
Comparative effectiveness of 2 β-blockers in hypertensive patients.
Parker ED, Margolis KL, Trower NK, Magid DJ, Tavel HM, Shetterly SM, Ho PM, Swain BE, O'Connor PJ. Parker ED, et al. Arch Intern Med. 2012 Oct 8;172(18):1406-12. doi: 10.1001/archinternmed.2012.4276. Arch Intern Med. 2012. PMID: 22928181 Free PMC article.
Clinical profile of eprosartan: a different angiotensin II receptor blocker.
Blankestijn PJ, Rupp H. Blankestijn PJ, et al. Cardiovasc Hematol Agents Med Chem. 2008 Oct;6(4):253-7. doi: 10.2174/187152508785909500. Cardiovasc Hematol Agents Med Chem. 2008. PMID: 18855637 Free PMC article. Review.
Does atenolol differ from other beta-adrenergic blockers?
Aursnes I, Osnes JB, Tvete IF, Gåsemyr J, Natvig B. Aursnes I, et al. BMC Clin Pharmacol. 2007 May 8;7:4. doi: 10.1186/1472-6904-7-4. BMC Clin Pharmacol. 2007. PMID: 17488499 Free PMC article.

See all "Cited by" articles

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information